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Abstract
The identification and adoption of diagnostic and prognostic biomarkers for rheumatoid arthritis has informed 
and improved the clinical management of this disease. With the advent of biologic treatments such as anti-Tumour 
Necrosis Factor (anti-TNF) therapy, achieving disease remission has become a realistic endpoint for clinicians. The 
life-changing efficacy of these therapies however is restricted to the 60-70% of patients who respond. The immune 
reaction to anti-inflammatory therapy is thought to be influenced by many genes which cumulatively contribute to a 
threshold for response. There is an inherent clinical need to provide theranostic biomarkers which could determine 
treatment outcome. The current role of genetic biomarkers in diagnosis, prognosis and predicting response to anti-
TNF therapy are discussed. 
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Introduction
The field of biomarker research has expanded dramatically in the 
past 5-7 years coinciding with the advancement of high-throughput 
technologies such as genomic and proteomic arrays. A biomarker 
can be generally defined as a measurable indicator of either normal 
or pathogenic processes or pharmacological responses to therapeutic 
interventions [1]. Clinically, biomarkers are commonly used for 
diagnostic (disease identification) and prognostic (predicted outcome 
or progression) purposes. However the availability of biomarkers which 
support treatment choice (theranostic biomarkers) remains limited. A 
theranostic biomarker could identify the most appropriate treatment 
for an individual, indicate the correct dose, or predict response to 
treatment. This approach attempts to maximise drug efficacy, minimise 
toxicity and provides a more informed treatment choice. 
Rheumatoid arthritis (RA) is a chronic inflammatory disease which 
affects up to 1 % of the population world-wide [2]. RA is particularly 
suited and consequently one of the more developed disease areas 
where biomarkers have been applied. The genetic basis of diagnostic, 
prognostic and potential theranostic biomarkers of RA are discussed 
in this brief review. 
RA Diagnostic and Prognostic Biomarkers
The association of RA with the Major Histocompatibility Complex 
(MHC) has been well documented, in particular the HLA-DRB1 locus 
is thought to account for around 30% of RA genetic risk [3,4]. HLA-
DRB1 alleles such as HLA-DRB1*0401 and HLA-DRB1*0404 share 
a similar amino acid sequence, known as the shared epitope (HLA-
SE), which may be specific to particular peptides related to disease 
[5,6]. RA patients with the HLA-DRB1*0401 and DRB1*0404 alleles 
have been shown to have increased radiological erosions and joint 
replacement compared to individuals without these alleles [7]. The 
genetic complexities of the HLA complex in RA are further reviewed 
by Jawaheer et al. [8]. Multiple studies of genes within and outside the 
MHC region have been carried out to identify and validate RA risk 
markers. These concerted efforts in over 40,000 samples have led to 
confirmation of 31 loci associated with RA risk [9]. While HLA-SE 
detection remains the most common genetic variant which is tested for 
in RA patients, incorporation of these relatively new loci into genetic 
tests for RA may become commonplace in the near future. 
RA can be serologically characterised by the presence of 
autoantibodies such as Rheumatoid Factor (RF) or Anti-cyclic 
Citrullinated Protein Antibodies (ACPA), which are present in about 
two thirds of individuals with the disease [10]. Rheumatoid factor are 
circulating autoantibodies (predominantly IgG and IgM) released by 
B cells directed against the Fc fragment of IgG molecules forming 
immune complexes. These immune complexes are known to activate 
the complement pathway thereby contributing to inflammation. 
Although widely used, the diagnostic specificity and sensitivity of RF is 
limited as it may also be present in other connective tissue or infectious 
disease states [11]. ACPA such as anti-CCP antibodies directed against 
peptides such as fillaggrin, keratin and vimentin have been shown to be 
highly specific (>95 %) to RA [12]. Anti-CCP antibodies have similar 
sensitivity to RF but display much greater specificity to the disease 
[13]. The American College of Rheumatology (ACR) guidelines for RA 
classification, revised in 2010, now requires that at least one serological 
test such as RF or ACPA is included in the clinical evaluation for 
‘definite RA’ diagnosis [14]. In addition to their use as diagnostic 
markers, RF and/or ACPA antibodies also carry prognostic value in 
RA. In early RA, the presence of RF is an independent predictor of 
erosive disease as shown in cohorts followed up for 5-12 years [15,16]. 
The presence of anti-CCP has also been identified a predictor of poor 
prognosis in terms of disease severity and joint damage [17-19]. Many 
studies have identified that anti-CCP positivity and higher titres 
are associated with MHC genes such as the HLA-SE alleles [20-25]. 
Conversely, HLA-DRB1-*03 alleles have been associated with lower 
anti-CCP titre [26,27]. The presence of genetic factors which influence 
the production and titre of autoantibodies are therefore potential 
indicators of a more aggressive phenotype in RA and could find utility 
in informing treatment decisions. 
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Treatment in RA 
Methotrexate (MTX) has long been considered the ‘gold standard’ 
disease modifying anti-rheumatic drug (DMARD) for RA. However, in 
the past decade treatment paradigms have been dramatically changed 
by the introduction of biologic therapies which specifically target 
molecules involved in disease pathogenesis. Biologic therapies for RA 
have revolutionised clinical outcomes where disease remission has 
become a realistic goal for individuals with moderate to severe RA. 
Current biologics available or in development for RA have 
mechanisms of action which interfere with pivotal chemical mediators 
or cell types which are involved in the RA inflammatory response. These 
include those directed against cytokine actions such as anti-TNF, anti-
IL-1 and anti-IL-6 and also those directed against cell surface receptors 
involved in T and B cell activation, such as anti-CD28 and anti CD-20 
respectively. The anti-TNF therapies such as adalimumab (Humira®, a 
fully human monoclonal antibody), infliximab (Remicade®, a chimeric 
monoclonal antibody) and TNF receptor protein etanercept (Enbrel 
®) have been available for more than 10 years. Certolizumab (Cimzia 
®, a pegylated humanized monoclonal antibody) and Golimumab 
(Simponi ®, a fully human monoclonal antibody) are newer alternative 
options within this drug class. 
In the UK, anti-TNF therapy is recommended in patients who 
have failed at least two other DMARDs including MTX and have active 
disease defined by a disease activity score in 28 joints [DAS28]of >5.1 
[28]. Although anti-TNF therapies have demonstrated remarkable 
efficacy there are a subset of patients (30-40%) who do not achieve 
clinical response to therapy. The reasons for this remain unknown; 
however given the heterogeneous nature of RA, response is likely 
influenced by many different pathways. The associated expense, the 
detrimental effect of inefficacious therapy in terms of progressive joint 
destruction and exposure to potentially harmful side-effects has led 
to an influx of studies to identify biomarkers to predict response to 
therapy. Many different pathways have been examined for potential 
biomarkers including the inflammatory, immune response, protein 
synthesis, apoptotic and mitochondrial oxido-reduction pathways. 
Within these pathways, genetic, cellular, and protein factors have been 
investigated as potential theranostic biomarkers which could enable 
informed treatment decisions at an individual level. It is likely that a 
genetic predisposition promoting restoration of the immune system 
balance is advantageous for response to therapy. The remainder of 
this review examines some of the genes which may be involved in this 
process and have been associated with response. 
Theranostic biomarkers and response to anti-TNF therapy
There are two main types of genetic approaches to look for 
biomarkers of treatment response. These are candidate gene studies and 
genome wide association studies (GWAS). Candidate studies generally 
involve genes which have already been related to RA (such as disease 
risk / susceptibility genes) or pathways involved in the RA process 
or pathogenesis. The first investigations were thus based on probable 
involvement of polymorphisms affecting the gene function and 
signalling pathways of cytokines involved in RA pathogenesis, such as 
TNF. There has been considerable data accumulated here, in particular 
with regard to single nucleotide polymorphisms (SNPs) which effect 
the TNF promoter such as -308G>A, and -857C>T. Reports on TNF–
308G/A have indicated that a genetic predisposition toward increased 
TNF expression (carrying the A allele) can be associated with non-
response to anti-TNF therapy [29-32]. These findings however have 
been disputed in a recent meta-analysis by Pavy et al and so the role 
of this SNP remains unclear [33]. In addition to studies of TNF, SNPs 
within other cytokine genes such as IL-10, TGF-B1, IL-1B and the IL-1 
receptor antagonist IL-RA have also been examined where opposing 
associations as biomarkers for response and non-response are reported 
[34,35]. These conflicting data highlight the need for studies examining 
the functional role of identified SNPs in RA pathogenesis. 
Signalling pathways involved in the propagation of chronic 
inflammatory processes are also potential sources of biomarkers for 
response to anti-inflammatory therapies such as anti-TNF. These 
include mechanisms driving and regulating the immune cell responses 
such as Toll- like receptor (TLR), NF kappa B (NFĸB) and P38 mitogen 
activated protein kinase (MAPK) signalling pathways. 
SNPs located within the TLR and NF-ĸB pathways such as rTLR 
signalling protein MyD88 (rs7744) and kinase CHUK (rs11591741) 
have been demonstrated to be associated with good response to 
anti-TNF therapy [36]. MyD88 and CHUK play integral roles in 
the NFĸB signalling system, effecting TNF production and chronic 
inflammatory processes [37,38]. Interestingly, these two SNPs (rs7744 
and rs11591741) remained significant against DAS28 or European 
League Against Rheumatism (EULAR) response criteria, where others 
lost significance.
The P38 signalling pathway which plays a major role in cytokine 
production, inflammation, and apoptosis has also been a pathway 
of interest for possible biomarkers. Response to anti-TNF therapy 
has been associated with SNPs within the genes coding for MAP3K1 
(rs96844), MAP3K14 (rs4792847) [39] and MAP2K6 (rs11656130) 
[40] proteins. These findings demonstrate a likely importance of this 
pathway for understanding response.
Receptor-ligand interactions which can influence the magnitude 
and duration of immune responses also warrant consideration as 
biomarkers. Inherited predisposition to an activating or inhibitory 
immune capacity for response to any insult could critically influence 
the restoration of balance and tolerance required for therapy to be 
effective. 
Killer-cell immunoglobulin-like receptors (KIR) are expressed on 
NK cells and T-cell subsets and play a role in balancing the activation/
inhibition thresholds for these cells in response to HLA antigens. The 
importance of HLA ligands and KIR in influencing susceptibility, 
immune response and outcomes to infections and inflammatory 
diseases are well documented. In a recent candidate gene study a KIR-
HLA combination that favours NK cell activation through the presence 
of activating KIR2DS2 and homozygosity for HLA-C1 or HLA-C2 
was associated with responders to anti-TNF therapy [41]. These KIR 
and HLA-C biomarker findings require replication in larger cohorts, 
however the NK cell activating biomarker signature in responders is 
in agreement with a recently reported observation of an expanded 
population of activated NK cells in responders compared to non- 
responders [42]. Interestingly, an allele (HLA-C.*0701) attributed to 
the responder population in this study, has also recently been identified 
as a RA susceptibility gene [43].
The exponential increase in RA susceptibility genes in recent years 
has also led to examination of newly identified risk genes as potential 
biomarkers for response to therapy. It is possible that RA risk alleles 
may play a functional role in RA and response to therapy but they 
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could also simply be in linkage disequilibrium with another gene 
which actively contributes to RA or response. There are several risk 
genes however which given their function may also play important 
roles in response to therapy. CD226 is a membrane protein expressed 
on the surface of NK, T-cell and B cell subsets and plays a role in their 
activation and inhibition. A Gly307Ser substitution in the CD226 
gene caused by SNP (rs763361) has been associated with autoimmune 
susceptibility, including RA, and also poor response to anti-TNF 
therapy [44,45]. It is possible that the cytoplasmic tail location of this 
SNP could alter the expression or signalling capability of this protein, 
effecting inflammatory responses. In the same study susceptibility gene 
AFF3 was investigated. AFF3 encodes a family of transcription factors 
which are preferentially expressed on lymphoid cells [46]. Carriage 
of the G allele (rs10865035) has recently been weakly associated with 
good response to anti-TNF therapy [45]. 
Currently one of the forerunners for theranostic biomarkers is the 
Protein tyrosine phosphatase receptor–C (PTPRC) gene also known as 
CD45. PTPRC performs essential modulation of T and B-cell responses 
by negatively regulating cytokine receptor signalling [47]. PTPRC is an 
RA susceptibility gene [48] which has been demonstrated to play a dual 
role in both risk and response to anti-TNF therapy in RA. In a large 
study of 9 RA cohorts carriership of the G allele (rs10919563) at the 
PTPRC locus was associated with good response to anti-TNF therapy 
[49]. The association of the PTPRC locus with response to therapy has 
since been replicated in an additional large cohort which appears to 
confirm the biomarker potential of this SNP [50].
Chronic inflammation is the net result of many genetic influences 
and thus the multiple effects of an anti-inflammatory drug such as 
anti-TNF are unlikely to be altered by a single gene or pathway. This 
is supported by the current failure to identify a single dominant gene 
which can predict response to therapy in RA. The attentions of many 
research groups now focus toward multi-gene/pathway panels and 
GWAS. With these approaches it may be possible to produce gene-
panels will provide the most powerful predictive combination for 
response to therapy and enable theranostic solutions in RA. 
Considerations
It is difficult to ascertain if a biomarker for response to therapy 
affects treatment outcomes through effecting disease risk, diagnosis, 
prognosis or directly undermines treatment efficacy. Currently accepted 
biomarkers for RA appear to have influence in each of these categories. 
This is demonstrated by HLA allele carriage which can influence disease 
susceptibility, the production of autoantibodies- effecting prognosis 
and also influence response to therapy. For example the HLA-SE, 
HLA-DRB1*03 alleles and HLA-DRA/BTNL2 SNP (rs1980493) have 
all been associated with the presence or absence of anti-CCP antibodies 
[26,27]. Subsequently, anti-CCP positivity and titre have been shown 
to adversely influence disease activity and response to anti-TNF 
treatment [51,27]. The precise functional role of these genes in each of 
these disease stages still remains to be determined. Perhaps genes such 
as the HLA loci which are known to influence RA from presentation to 
outcome will prove the most robust biomarkers and provide clues as to 
the aetiology of RA. 
The discovery of theranostic biomarkers is confounded by 
differences in the methods which are used to determine clinical response 
to therapy. The most commonly employed being DAS, ACR, EULAR, 
Simplified (SDAI) or Clinical (CDAI) Disease Activity Index criteria to 
assess disease activity and therefore treatment outcomes. Each method 
involves all or a combination of joint evaluation to varying degrees, 
and laboratory analysis of acute phase proteins such as Erythrocyte 
Sedimentation Rate (ESR) or C - reactive protein (CRP), and patient/
physician subjective measures for disease activity or pain. The clinical 
use of these methods have been reviewed and recommended by the 
ACR [52], however their adoption and translation is known to vary 
across rheumatology centres. Perhaps for a theranostic biomarker to 
be truly clinically useful, it should retain predictive value for response 
irrespective of the methods used to assess improvement in disease 
activity. 
The majority of studies for response biomarkers to date have 
incorporated several anti-TNF drugs within the ‘treated’ group, which 
carries potential for bias normally avoided in studies with cohort 
allocation. This collation of treated patients is likely driven by the 
necessity to sample large numbers of patients required for genetic 
analysis, from often financially limited patient populations. In fact, such 
studies which truly reflect ‘real life’ clinical practice, are perhaps the 
most likely to derive biomarkers which will remain useful as additional 
anti-TNF drugs join the treatment paradigm. Anti-TNF therapy was 
the first biologic class to come to market in RA. With the addition of 
alternative mechanism of action drugs such as rituximab and abatacept, 
the rheumatologist and patient now have options beyond anti-TNF 
therapy, making it even more valuable to have the ability to predict 
response to therapies. This will ensure the most appropriate treatment 
in a timely manner for each individual patient. 
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